Magnolia Medical launches Mission to Zero

Sept. 14, 2020—Magnolia Medical Technologies launched Mission to Zero, to bring greater awareness to the patient safety and antibiotic-associated risks caused by false-positive diagnostic test results for sepsis.

Magnolia is launching the initiative by partnering with emergency departments, critical care units, clinical laboratories, and infection prevention teams within acute care hospitals. Each team member makes an individual pledge to participate, the company says, which allows all departments to work in tandem to ensure the best possible patient outcomes and experience are achieved.

“We will achieve this mission through a combination of supporting change in national guidelines and benchmarks, Steripath technology solutions, and a strong partnership with our health care community—which begins with each individual patient, health care worker, and hospital uniting as one team,” Greg Bullington, CEO and co-founder of Magnolia Medical, said in a press statement. “As a team, we can help stop the significant clinical and economic challenges associated with false-positive blood culture results.”

The Steripath Gen2 ISDD product portfolio is an FDA 510(k)-cleared device platform indicated to reduce blood culture contamination. The device was cleared based on peer-reviewed published controlled clinical studies demonstrating Steripath’s ability to reduce blood culture contamination by 83 percent and 88 percent. The platform integrates user-controlled negative pressure to divert and sequester the initial 1.5 to 2.0 mL of blood collected for culture.